Posted: May 20, 2016
Dr. Dayan Goodenowe discusses the OvAware™ test for ovarian cancer in the following interviews and articles: Interview with John Gormley: Interview on CJME (at 5:20 in the clip): Saskatoon Home Page article: (http://www.saskatoonhomepage.ca/local-news/74123-saskatoon-development-could-reduce-ovarian-cancer-mortality-rates) Genome […]
Read More
Posted: May 12, 2016
SASKATOON, May 12, 2016 /PRNewswire/ – Using its proprietary metabolomics technology, Phenomenome Discoveries Inc. had previously discovered that specific metabolic abnormalities were present in the blood of women suffering from ovarian cancer. The company […]
Read More
Posted: May 6, 2016
PDI is pleased to announce the following upcoming presentations and FTI sales process events: FTI marketing events – Asia: Tokyo, Japan – May 23rd Shanghai, China – May 25th Hong Kong, China – May 27th […]
Read More
Posted: May 5, 2016
PDI is pleased to announce that the formal sales process has been approved (see information memorandum). The assets of PDI have been divided into six groups (Diagnostic Testing Unit, Cancer Diagnostics, Neurological Diagnostics, Therapeutics, Laboratory, […]
Read More
Posted: March 11, 2016
Phenomenome Discoveries Inc. (PDI) was founded in 2000 based upon a novel biomarker discovery technology called non-targeted complex sample analysis that was invented by its founder, Dr. Dayan Goodenowe. Since its founding, with the […]
Read More
